In this episode, we delve into the NIVEC study, a phase 2 trial investigating the use of nivolumab, a programmed cell death protein 1 inhibitor, as a neoadjuvant therapy for patients with mismatch repair deficient, surgically resectable endometrial cancer. The study explores whether this immunotherapy can improve complete response rates when combined with standard surgical and adjuvant treatments. We discuss the trial’s design, rationale, and the potential impact of immune checkpoint inhibitors in reshaping treatment strategies for this challenging cancer subtype. Tune in to learn how this research aims to address critical gaps in the management of endometrial cancer and improve patient outcomes.

A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC) (https://doi.org/10.3802/jgo.2025.36.e35)